QualityStocksNewsBreaks – Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) Preps ONC010 for Clinical Translation
Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) and may include paid advertising. Onco-Innovations (CBOE CA: ONCO)(OTCQB: ONNVF)(FSE: W1H) is advancing its preclinical oncology candidate ONC010, a nanoparticle-encapsulated PNKP inhibitor designed to disrupt DNA-repair mechanisms involved in cancer survival and treatment resistance, while building the manufacturing, regulatory and financial infrastructure needed for clinical development. The company reports completing a 300-gram API scale-up with approximately 99.3% purity, expanding manufacturing capabilities through a partnership with Nanosoft Polymers, and progressing metabolism, analytical, licensing and other IND-enabling activities. It has also arranged approximately CAD$5 million in institutional financing, to be released through 18 monthly tranches, to…